BR3003C

BR3003C is a code name for an investigational drug studied in combination with BR3003B and as part of the composite formulation BR3003. It has been evaluated in a randomized, open-label, single oral dose, two-way crossover clinical trial to assess its pharmacokinetics and safety profile in healthy adults. The study was sponsored by Boryung Pharmaceutical. While the precise composition or mechanism of action for BR3003C alone is not specified in available sources, it is likely related to metabolic or antidiabetic therapies given its association with other compounds targeting pathways such as PPARγ agonists, AMPK agonists, P-gp inhibitors, and SGLT2 inhibitors[5][1]. Further details on its specific molecular target or therapeutic indication are not provided.